Immatics N.V.
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Quick Facts
- Established: 2000
- Locations: Tuebingen and Munich, Germany and Houston, Texas, USA
- Employees: 250 +
- Proprietary pipeline: 7 product candidates, thereof 3 in clinical trials
- Partnered pipeline: 10 programs partnered with Amgen, Genmab, BMS, GSK
- Cancer targets: More than 200 prioritized cancer targets across multiple cancer indications
- IP position: Over 1,550 secured patents worldwide and over 320 granted patents in the US
- NASDAQ Ticker: IMTX
More information:
Link to Factsheet
Link to video “Immatics’ Therapeutic Approach”
For further information please see: www.immatics.com or contact us via info@immatics.com